The immune response is not unlike a game of chess, with white and black pieces playing opposing roles and orchestrating an opening, a middle and an endgame of innate immunity, adaptive immunity and resolution, respectively. After decades of research, the study of atheroimmunology has brought the first therapeutics to the clinic. Can we resynchronize the immune system in atherosclerosis and save the king?
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Dib, L. et al. Lipid-associated macrophages transition to an inflammatory state in human atherosclerosis increasing the risk of cerebrovascular complications. Nat. Cardiovasc. Res. 2, 656–672 (2023).
Fernandez, D. M. et al. Single-cell immune landscape of human atherosclerotic plaques. Nat. Med. 25, 1576–1588 (2019).
Porsch, F. & Binder, C. J. Autoimmune diseases and atherosclerotic cardiovascular disease. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-024-01045-7 (2024).
Maffia, P., Mauro, C., Case, A. & Kemper, C. Canonical and non-canonical roles of complement in atherosclerosis. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-024-01016-y (2024).
Döring, Y., van der Vorst, E. P. C. & Weber, C. Targeting immune cell recruitment in atherosclerosis. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-024-01023-z (2024).
Adkar, S. S. & Leeper, N. J. Efferocytosis in atherosclerosis. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-024-01037-7 (2024).
Fredman, G. & Serhan, C. N. Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-023-00984-x (2024).
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med 377, 1119–1131 (2017).
Tsiantoulas, D. et al. APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans. Nature 597, 92–96 (2021).
Lutgens, E. et al. Requirement for CD154 in the progression of atherosclerosis. Nat. Med. 5, 1313–1316 (1999).
Ait-Oufella, H. et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12, 178–180 (2006).
Gerlach, B. D. et al. Efferocytosis induces macrophage proliferation to help resolve tissue injury. Cell Metab 33, 2445–2463.e8 (2021).
Park, I. et al. C-type lectin receptor CLEC4A2 promotes tissue adaptation of macrophages and protects against atherosclerosis. Nat. Commun. 13, 215 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Monaco, C., Dib, L. Atheroimmunology: keeping the immune system in atherosclerosis in check. Nat Rev Cardiol 21, 737–738 (2024). https://doi.org/10.1038/s41569-024-01075-1
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41569-024-01075-1
